Plastic and Aesthetic Research

OAE Publishing Inc.
OAE Publishing Inc.
ISSN: 23479264, 23496150

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q3
SJR
0.321
CiteScore
2.0
Categories
Surgery
Areas
Medicine
Years of issue
2019-2025
journal names
Plastic and Aesthetic Research
Publications
582
Citations
1 888
h-index
17
Top-3 countries
USA (157 publications)
India (51 publications)
Italy (36 publications)

Most cited in 5 years

Found 
from chars
Publications found: 24792
Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]
Ho C., Soon Y.Y., Nichol A., Robledo K., Sahgal A., Pinkham M., Melosky B., Huang Y., Parmar A., Solomon B., Liu M., Tham I.W., Sacher A., Tey J.C., Menjak I., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Fuang H.G., Kulyaba Y., Zyuhal K., Scheusan R., Garassino M.C., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Hakozaki T., Tanaka K., Shiraishi Y., Sekino Y., Mitome N., Okuma Y., Aiba T., Utsumi T., Tanizaki J., Azuma K., Hara S., Morita R., Niho S., Yokoyama T., Toyozawa R., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Chen P., Wang H., Tang Z., Shi J., Cheng L., Zhao C., Li X., Zhou C.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reply to: “AI Technologies for Patients With Immune-Related Adverse Events”
O’Reilly D., O’Leary C., Naidoo J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
In this issue
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Navigating the Complexity of Cerebral Prophylaxis: A Path Worth Taking?
Ramella S., Fiore M., D’Angelillo R.M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reducing pERKs to Break “RAS”istance to Sotorasib
Gray S.G., O’Connor D., Mutti L., Meirson T.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Chu Q.S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Enlarging the Reach of Screening and Early Detection of Lung Cancer
Brown M., Myers R., Lam S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
A Response to the Letter to the Editor: “Reply to Lei Wu et al.”
Kim E.K., Bak M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Accurate Risk Factors of Cardiotoxicity in Patients With NSCLC Treated With Osimertinib
Wu L., Liu N., Sun M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu P., Li D., Zhang C., Sun N., He J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 1
Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing
Liu F., Li H.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0

Top-100

Citing journals

10
20
30
40
50
60
70
Show all (70 more)
10
20
30
40
50
60
70

Citing publishers

50
100
150
200
250
300
350
Show all (70 more)
50
100
150
200
250
300
350

Publishing organizations

1
2
3
4
5
6
7
8
9
Show all (70 more)
1
2
3
4
5
6
7
8
9

Publishing organizations in 5 years

1
2
3
4
5
Show all (70 more)
1
2
3
4
5

Publishing countries

20
40
60
80
100
120
140
160
USA, 157, 26.98%
India, 51, 8.76%
Italy, 36, 6.19%
China, 29, 4.98%
United Kingdom, 29, 4.98%
Spain, 18, 3.09%
Germany, 15, 2.58%
Republic of Korea, 12, 2.06%
Saudi Arabia, 12, 2.06%
Canada, 10, 1.72%
Switzerland, 8, 1.37%
Japan, 7, 1.2%
Belgium, 6, 1.03%
Mexico, 6, 1.03%
Serbia, 5, 0.86%
Turkey, 5, 0.86%
Australia, 4, 0.69%
Brazil, 4, 0.69%
Israel, 4, 0.69%
Colombia, 3, 0.52%
Sweden, 3, 0.52%
Hungary, 2, 0.34%
Iran, 2, 0.34%
Lebanon, 2, 0.34%
Malaysia, 2, 0.34%
Nigeria, 2, 0.34%
Netherlands, 2, 0.34%
New Zealand, 2, 0.34%
Chile, 2, 0.34%
France, 1, 0.17%
Portugal, 1, 0.17%
Bahrain, 1, 0.17%
Vietnam, 1, 0.17%
Georgia, 1, 0.17%
Egypt, 1, 0.17%
Zambia, 1, 0.17%
Qatar, 1, 0.17%
Malta, 1, 0.17%
Nepal, 1, 0.17%
Norway, 1, 0.17%
Tunisia, 1, 0.17%
Uruguay, 1, 0.17%
Show all (12 more)
20
40
60
80
100
120
140
160

Publishing countries in 5 years

20
40
60
80
100
120
USA, 102, 35.79%
Italy, 12, 4.21%
United Kingdom, 7, 2.46%
Spain, 6, 2.11%
China, 5, 1.75%
Japan, 5, 1.75%
India, 4, 1.4%
Saudi Arabia, 4, 1.4%
Serbia, 4, 1.4%
Switzerland, 4, 1.4%
Germany, 3, 1.05%
Canada, 3, 1.05%
Belgium, 2, 0.7%
Brazil, 2, 0.7%
Mexico, 2, 0.7%
Netherlands, 2, 0.7%
Sweden, 2, 0.7%
France, 1, 0.35%
Portugal, 1, 0.35%
Hungary, 1, 0.35%
Zambia, 1, 0.35%
Malta, 1, 0.35%
Republic of Korea, 1, 0.35%
Turkey, 1, 0.35%
Chile, 1, 0.35%
20
40
60
80
100
120